JPRN-jRCT1080225340已完成Unknown
General Drug Use-Results Survey of Onoact [Following the refractory and urgent fatal arrhythmia: ventricular fibrillation and hemodynamically unstable ventricular tachycardia ]
ONO PHARMACEUTICAL CO., LTD.0 个研究点目标入组 200 人开始时间: 2020年8月24日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients will be registered as subjects in this survey if they are the following refractory and urgent fatal arrhythmia: ventricular fibrillation and hemodynamically unstable ventricular tachycardia, which is specified as indication of the drug, and they have no previous history of treatment with the drug on this indication.
排除标准
- 未提供
研究者
相似试验
已完成
Unknown
Special Drug Use-Results Survey of Onoacttachyarrhythmia, atrial fibrillation/atrial flutter in patients with cardiac dysfunctionJPRN-jRCT1080222572ONO PHARMACEUTICAL CO., LTD.800
进行中（未招募）
不适用
43-301 : Special Drug Use-Results Survey of ONGENTYSParkinson's diseaseJPRN-jRCT2011210013Kuro Toshihiko250
Unknown
Unknown
Drug Use-Results Survey of OPDIVO (malignant melanoma)Malignant melanomaJPRN-jRCT1080223217ONO PHARMACEUTICAL CO., LTD.1,700
已完成
Unknown
Drug Use-Results Survey of OPDIVO (head and neck cancer)Head and Neck CancerJPRN-jRCT1080224012ONO PHARMACEUTICAL CO.,LTD.400
已完成
不适用
Special Drug Use-Results Survey for Long-term Use of XEPLION TRI Aqueous Suspension for IM Injection 175 mg, 263 mg, 350 mg, and 525 mg SyringeSchizophreniaJPRN-UMIN000042033Janssen Pharma990